Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

3.800

+0.130 (3.54%)

Jul 2, 2026, 4:00 PM EDT - Market closed

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Research and Development Agreements Revenue	65.74M	74.26M	58.49M
Research and Development Agreements Revenue Growth	-11.47%	26.96%	33.30%
Grant Revenue	669.00K	425.00K	351.00K
Grant Revenue Growth	57.41%	21.08%	-49.79%
Revenue (Other)	1,000.00	-	-
Revenue (Total)	66.41M	74.68M	58.84M
Revenue (Total) Growth	-11.08%	26.92%	32.00%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States Revenue	-	39.34M	57.38M
United States Revenue Growth	-	-31.43%	30.98%
United Kingdom Revenue	-	35.34M	1.14M
United Kingdom Revenue Growth	-	3013.39%	-
Other Geographic Revenue	-	-	327.00K
Other Geographic Revenue Growth	-	-	-57.48%
Revenue (Total)	66.41M	74.68M	58.84M
Revenue (Total) Growth	-11.08%	26.92%	32.00%